Thrombosis prophylaxis with low molecular weight heparin in total hip replacement.
In a randomized prospective trial, the efficacy of low molecular weight heparin (LMWH) (Fragmin) and dextran 70 (Macrodex) in preventing deep vein thrombosis (DVT) in the legs was evaluated in 98 consecutive patients undergoing elective total hip replacement. The patients were randomly allocated to receive either 2500 anti-factor Xa units LMWH twice daily for 7 days, with the first dose given 2 h before surgery; or 500 ml dextran 70 twice during the day of operation, followed by a single infusion of 500 ml on the first and again on the third postoperative day. DVT was assessed by 125I-fibrinogen test for 2 weeks postoperatively, a positive test being followed by phlebography. DVT developed in 22 (45 per cent) of 49 patients receiving dextran 70 and in 10 (20 per cent) of 49 patients in the LMWH group (P less than 0.01). LMWH was thus statistically significantly better than dextran 70 in preventing DVT in the legs. It was not firmly established whether this benefit was also valid in the high ileofemoral region. Two patients with non-fatal pulmonary embolism were found in each group. Per- and postoperative blood loss and blood transfusion requirements were significantly lower in the LMWH group.
Eriksson
B I
BI
Department of Orthopaedics, Ostra sjukhuset, Göteborg, Sweden.
Zachrisson
B E
BE
Teger-Nilsson
A C
AC
Risberg
B
B
D000368:Aged; D002986:Clinical Trials as Topic; D003911:Dextrans / Q000627:therapeutic use; D015951:Factor Xa; D005260:Female; D006470:Hemorrhage / Q000517:prevention & control; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use*; D006622:Hip Prosthesis; D006801:Humans; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000517:prevention & control*; D011446:Prospective Studies; D011897:Random Allocation; D015842:Serine Proteinase Inhibitors; D013924:Thrombophlebitis / Q000517:prevention & control*; D013997:Time Factors
D003911:Dextrans; D006495:Heparin, Low-Molecular-Weight; D015842:Serine Proteinase Inhibitors; D015951:Factor Xa